Stemline rallies after outlining results from additional vaccine study

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Stemline Therapeutics (STML +11.6%) enjoys a strong session after announcing late Friday evening that the results of a clinical trial of SL-701 in low-grade glioma were being presented at a Meeting of the World Federation of Neuro-Oncology.

The company says an abstract shows the vaccine is "well-tolerated and induced specific and sustained immune responses against its brain tumor targets."

Additionally, STML says the results show "patients with a high magnitude of immunologic responsiveness experienced prolonged progression free survival." (PR)